Pivotal Trial of the Boomerang Catheter for pDVA

Официальное название

Pivotal Multicenter Trial of the Boomerang® Catheter for Percutaneous Deep Vein Arterialization (pDVA)

Обзор

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

Вмешательства

• Устройство Boomerang Catheter
  The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.

Первичные конечные точки

• Amputation Free Survival (AFS) [Срок оценки: 6-months]

Вторичные конечные точки (8)

• Technical success [Срок оценки: During index procedure]
• Procedural success [Срок оценки: Immediately post index procedure]
• Limb salvage [Срок оценки: 3 years post index procedure]
• Primary patency [Срок оценки: 1 year post index procedure]
• Primary assisted patency [Срок оценки: 1 year post index procedure]
• Secondary patency [Срок оценки: 1 year post index procedure]
• Target wound healing [Срок оценки: 1, 3, 6, 9-months, and 1-year]
• Complete wound healing [Срок оценки: 1, 3, 6, 9-months, and 1-year]

Критерии участия

Критерии включения

• Patient is age ≥ 18 years
• Patient has confirmed clinical diagnosis of Rutherford Category (RC) 5 or 6 Chronic Limb-Threatening Ischemia (CLTI) with previous angiogram or hemodynamic evidence (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) demonstrating severely diminished arterial perfusion of the index limb.
• Assessment by the PI and an Independent Review Committee (IRC) determines that patient has no option for conventional distal bypass, surgical or endovascular therapy for limb salvage.
• Inflow artery criteria:

• Imaging confirmation of patent inflow artery (< 50% stenosis) from Aortic bifurcation to tibial trifurcation.
• Target conduit vein criteria:

• Duplex ultrasound confirms that vein is free from thrombus, contiguous from the intended anastomosis site through the lateral plantar vein, and ≥ 2.0mm lumen-lumen diameter (with tourniquet applied) throughout.
• Patient may be scheduled for a planned minor amputation (toe, ray, or trans-metatarsal) within 30 days after index procedure.
• Prior stent(s) to inflow arteries (i.e., Iliac, SFA, Popliteal) are allowed.
• Patient is willing and able to provide written informed consent.
• Patient meets institutional criteria for procedure clearance and is able to comply with study requirements per PI judgement.
• Diabetic patients have adequate glycemic control per investigator judgement.
• Female patients of childbearing potential have a negative pregnancy test within 7 days prior to index procedure (urine)
• Patient is enrolled in a wound care network and has an adequate support network to ensure compliance with medication regimen and follow-up study visits.
• PI determines that the primary wound is stable (e.g., not rapidly deteriorating or showing signs of healing).

Критерии исключения

• Life expectancy < 12 months.
• Patient has a lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle).
• Patient is dialysis dependent.
• Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in patients not undergoing dialysis.
• Prior peripheral arterial bypass procedure on index limb within 30 days.
• Previous major amputation of the target limb or absence of adequate viable tissue for below-ankle (e.g., mid-foot) amputation.
• Patient is non-ambulatory due to above-ankle amputation of contralateral limb.
• The patient is currently participating in another investigational drug or device study that has not completed the primary endpoint and that clinically interferes with the endpoints of this study per PI judgement.
• Patient has known hypersensitivity or contraindication to materials used during the procedure (cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers) or a known contrast sensitivity that cannot be adequately pre-medicated.
• Patient cannot be adequately treated with study medications due to known contraindication to aspirin, ADP antagonists such clopidogrel, prasugrel or ticagrelor, or anticoagulants such as heparin or bivalirudin.
• Patient has had a stroke within the previous 3 months with residual Rankin score of ≥ 2.
• NYHA Class IV heart failure which may compromise patient's ability to safely undergo a percutaneous procedure, per PI judgment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 25 центров

• Arrowhead Regional Medical Center — San Bernardino
• Olive View-UCLA Medical Center — Sylmar
• Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance
• PIH Whittier Hospital — Whittier
• EndoVascular Consultants — Wilmington
• First Coast Cardiovascular Institute — Jacksonville
• Rush University Medical Center — Chicago
• Cardiovascular Institute of the South — Houma
• … и ещё 17 центров

Идентификаторы

NCT: NCT06311773 · Protocol # 24-01

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗